232 related articles for article (PubMed ID: 29408333)
1. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.
Arredondo-García JL; Hadinegoro SR; Reynales H; Chua MN; Rivera Medina DM; Chotpitayasunondh T; Tran NH; Deseda CC; Wirawan DN; Cortés Supelano M; Frago C; Langevin E; Coronel D; Laot T; Perroud AP; Sanchez L; Bonaparte M; Limkittikul K; Chansinghakul D; Gailhardou S; Noriega F; Wartel TA; Bouckenooghe A; Zambrano B;
Clin Microbiol Infect; 2018 Jul; 24(7):755-763. PubMed ID: 29408333
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
4. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
Hadinegoro SR; Arredondo-García JL; Capeding MR; Deseda C; Chotpitayasunondh T; Dietze R; Muhammad Ismail HI; Reynales H; Limkittikul K; Rivera-Medina DM; Tran HN; Bouckenooghe A; Chansinghakul D; Cortés M; Fanouillere K; Forrat R; Frago C; Gailhardou S; Jackson N; Noriega F; Plennevaux E; Wartel TA; Zambrano B; Saville M;
N Engl J Med; 2015 Sep; 373(13):1195-206. PubMed ID: 26214039
[TBL] [Abstract][Full Text] [Related]
6. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
[TBL] [Abstract][Full Text] [Related]
7. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
[TBL] [Abstract][Full Text] [Related]
8. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
[TBL] [Abstract][Full Text] [Related]
9. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
L'Azou M; Moureau A; Sarti E; Nealon J; Zambrano B; Wartel TA; Villar L; Capeding MR; Ochiai RL; ;
N Engl J Med; 2016 Mar; 374(12):1155-66. PubMed ID: 27007959
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
Biswal S; Reynales H; Saez-Llorens X; Lopez P; Borja-Tabora C; Kosalaraksa P; Sirivichayakul C; Watanaveeradej V; Rivera L; Espinoza F; Fernando L; Dietze R; Luz K; Venâncio da Cunha R; Jimeno J; López-Medina E; Borkowski A; Brose M; Rauscher M; LeFevre I; Bizjajeva S; Bravo L; Wallace D;
N Engl J Med; 2019 Nov; 381(21):2009-2019. PubMed ID: 31693803
[TBL] [Abstract][Full Text] [Related]
14. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
[TBL] [Abstract][Full Text] [Related]
15. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
16. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.
Halstead SB
Am J Trop Med Hyg; 2016 Oct; 95(4):741-745. PubMed ID: 27352870
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
Harenberg A; de Montfort A; Jantet-Blaudez F; Bonaparte M; Boudet F; Saville M; Jackson N; Guy B
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004830. PubMed ID: 27459266
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Dayan GH; Langevin E; Gilbert PB; Wu Y; Moodie Z; Forrat R; Price B; Frago C; Bouckenooghe A; Cortes M; Noriega F; DiazGranados CA
Vaccine; 2020 Apr; 38(19):3531-3536. PubMed ID: 32204943
[TBL] [Abstract][Full Text] [Related]
19. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
[TBL] [Abstract][Full Text] [Related]
20. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
Tran NH; Chansinghakul D; Chong CY; Low CY; Shek LP; Luong CQ; Fargo C; Wartel TA; Sun S; Skipetrova A; Bouckenooghe A
Hum Vaccin Immunother; 2019; 15(10):2315-2327. PubMed ID: 30724660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
